What is HC Wainwright’s Forecast for PVLA FY2029 Earnings?

Palvella Therapeutics (NASDAQ:PVLA) – Investment analysts at HC Wainwright issued their FY2029 EPS estimates for shares of Palvella Therapeutics in a research report issued to clients and investors on Friday, January 3rd. HC Wainwright analyst A. Fein forecasts that the company will earn ($0.69) per share for the year. HC Wainwright currently has a “Buy” rating and a $38.00 target price on the stock.

Separately, Cantor Fitzgerald initiated coverage on shares of Palvella Therapeutics in a research report on Wednesday, December 18th. They set an “overweight” rating for the company.

Palvella Therapeutics Stock Down 0.2 %

Shares of NASDAQ PVLA opened at $14.73 on Monday. Palvella Therapeutics has a 52 week low of $6.20 and a 52 week high of $22.32. The stock has a market capitalization of $19.44 million, a P/E ratio of -1.22 and a beta of 0.67.

Insider Activity

In other Palvella Therapeutics news, Director George M. Jenkins purchased 4,000 shares of Palvella Therapeutics stock in a transaction on Wednesday, December 18th. The shares were bought at an average price of $12.93 per share, with a total value of $51,720.00. Following the completion of the acquisition, the director now directly owns 180,671 shares of the company’s stock, valued at approximately $2,336,076.03. This trade represents a 2.26 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 6.39% of the company’s stock.